Efficacy for Reduction of HbA1c and Body Weight by Oral Semaglutide (Rybelsus)

機関リポジトリ

抄録

Background: Oral semaglutide (Rybelsus) has been recently in focus for type 2 diabetes (T2D). Case presentation: Case is 61-year-old female with T2D, obesity, fatty liver and Gastro Esophageal Reflux Disease (GERD). Her HbA1c was 13.2% in Dec 2021, and she started to have metformin, empagliflozin and Rybelsus from 3mg to 7mg/day. General situation was improved as -4.2% of HbA1c and -8kg in weight for 4 months. Discussion and Conclusion: This case has GERD, and then the doses of Rybelsus kept 7mg/day. She did not feel any gastrointestinal adverse effects (GIAEs). This impressive case will become reference for diabetic practice.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ